Tech Company Financing Transactions
TherAchon Funding Round
TherAchon, based in Basel, received $35 million in funding from OrbiMed, New Enterprise Associates and Versant Ventures.
Transaction Overview
Company Name
Announced On
10/1/2015
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Series A
Investors
Proceeds Purpose
The funds will be used to advance Therachon's Lead program, a soluble form of human fibroblast growth factor receptor 3, through clinical proof of concept.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
Aeschenvorstadt 36
Basel, 4051
Switzerland
Basel, 4051
Switzerland
Phone
Undisclosed
Website
Email Address
Overview
TherAchon is a biotech compagny, specialized in research and development for achondroplasia and its associated complications. It is a spin off of the Mediterranean Center of Molecular Medicine, Inserm Unit 1065 based in Nice, France.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Luca Santarelli
Chief Financial Officer
Claudia D'Augusta
Chief Medical Officer
Christian Meyer
Chief Operating Officer
Richard Porter
Vice President
Jeffrey Stavenhagen
VP - Bus. Development
Behrad Derakhshan
Browse more venture capital transactions:
Prev: 10/1/2015: Peaxy venture capital transaction
Next: 10/1/2015: NewStore venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on funding rounds that are announced publicly. All VC database entries reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs